TRUTH and Lyme Vaccines


A vaccine to prevent Lyme disease is being fast-tracked for approval by the U.S. Food and Drug Administration to address what public health officials say is the most rapidly growing vector-borne disease in the United States.

Currently, there is no Lyme vaccine for humans, although one is available for dogs. The human vaccine being expedited for approval by the FDA is known in its preapproval phase as VLA15, a product of French vaccine-maker Valneva. Only 180 participants in a preliminary clinical trial have received the inoculation so far.

Valneva has been authorized to move its research into the FDA’s program called Fast Track. Designated products are aimed at unmet medical needs, agency officials said.

“The incidence of Lyme disease has increased dramatically,” said Dr. Benjamin Luft, the Edmund D. Pellegrino Professor of Medicine at Stony Brook University and a specialist in infectious diseases. He said the number of people who have contracted Lyme disease and other tick-related illnesses has risen as the bugs have expanded their range.

The Borrelia burgdorferi bacterium, which causes Lyme disease, is shown in this electron micrograph image. Photo Credit: Alamy Stock Photo / RGB Ventures

Luft, who himself has developed a Lyme vaccine, said that any inoculation aimed at Borrelia burgdorferi — the bacterium that causes Lyme disease — must address the variations seen in the organism. Otherwise, he said, the vaccine is of no benefit to those who receive it.

( See Antigenic Variation below )

Luft’s vaccine was licensed to the Illinois-based Baxter pharmaceutical company, but the license now is held by Shire Plc, he said.

Shire, with headquarters in Dublin, Ireland, acquired Baxter’s biopharmaceutical division last year.

Valneva officials, meanwhile, said their vaccine appears to be effective against the six most common types of B. burgdorferi that are prevalent in the United States and Europe. Under the fast-track designation, the company will advance to a larger clinical study of the vaccine early next year.

Dr. Benjamin Luft, the Edmund D. Pellegrino Professor of Medicine at Stony Brook University and a specialist in infectious diseases, is shown on Sept. 6, 2016. Photo Credit: Ed Betz



Before you and your loved ones start lining up, you may want to take a look back at it’s predecessor LYMErix.

Antibody is taken up into tick and bacteria destroyed in vector. 0, 1 and 12 months. As of February 25, 2002 LYMErix™ off the market.
Lyme Disease Vaccine (Recombinant OspA)
LYMErix [Lyme Disease Vaccine (Recombinant OspA)] is a
noninfectious recombinant vaccine developed and manufactured by SmithKline Beecham Biologicals. Thecausative agent of Lyme disease is Borrelia burgdorferi; in
North America, all Lyme disease is due to Borrelia burgdorferi sensu stricto. The vaccine contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli. Lipoprotein OspA is a single polypeptide chain of 257 amino acids with lipids covalently bonded to the N terminus. No substance of animal origin is used in the commercial manufacturing
process. Fermentation media consist primarily of inorganic salts, and vitamins, with small quantities of antifoam (contains silicon), kanamycin sulfate (anaminoglycoside
antibiotic), and yeast extract. Silicon and kanamycin are removed to levels below detection ( <7 ppm and <10 ppb,respectively). The vaccine is adsorbed onto aluminum hydroxide.
LYMErix is supplied as a sterile suspension in single-dose vials and prefilled syringes for intramuscular administration. The vaccine is ready for use without reconstitution; it must be shaken before administration to ensure a uniform turbid
white suspension.
Each 0.5mL dose of vaccine consists of 30 mcg of lipoprotein OspA adsorbed onto 0.5 mg aluminum as aluminum hydroxide adjuvant. Each dose of the vaccine
preparation contains 10 mM phosphate buffered saline and 2.5 mg of 2 phenoxyethanol, abacteriostatic agent.


Remember OspA is a Triacylated-lipoprotein, Pam3cys! It is a TLR2/1 agonist or a fungal toxin, which turns off the immune response to prevent death from septic shock. OspA can not be a vaccine because it is what causes the disease, not the spirochetes! If you have [Lyme], you have LYMErix, if you had LYMErix, you have [Lyme].

and they shed their outer surface in a mechanism called blebbing.


Through “antigenic variation,” or the ability to modify their outer surface proteins (Osps), the organism causes “relapsing fever.” Because the host immune response, (your immune system), must constantly address the variable antigens, (an antigen is a harmful substance that causes the body to produce antibodies). For this reason, it is not possible to vaccinate against borrelia.

“1986, Alan Barbour. Spirochetes bleb or pinch off bits to release its surface proteins stealth bombing or turning off the immune system. “It’s using some sort of stealth-bomber-type mechanism,” he says. Or, using another diversionary tactic called blebbing, the spirochete can pinch off bits of its membrane in order to release its surface proteins. “It’s like a bacterial Star Wars defense program.”


     Both the vaccine and Borrelia Burgdorferi contain OspA, a highly toxic immune-suppressing triacyl lipoprotein, (“a lipoprotein is a biochemical assembly whose purpose is to transport hydrophobic lipid (a.k.a. fat) molecules in water, as in blood or extracellular fluid.”).Lipoproteins in bacteria: structures and pathways

LYMErix Vaccine Adverse Events Reports

Below is a diagram of the new Lyme vaccine VLA15. Look carefully and see if anything looks familiar. No, you don’t need to be a chemist to see it.

Pic 1 lyme vaccine

Figure 1. Localization of the stabilizing disulfide bonds and schematic representation of the heterodimers.
Left panel: Part of the OspA serotype 1 crystal structure showing the monomer protein (Protein Data Bank accession 1OSP [34]). Locations of the five modifications: “A” (aa 141∶ 241), “B” (aa 182∶ 269), “C” (aa 244∶ 259), “D” (aa 165∶ 265) and “E” (aa 182∶ 272) are indicated as dotted lines between the β-carbon atoms of the corresponding residues. Right panel: Schematic illustration of two stabilized monomers joined with a linker sequence to form one heterodimer. The α-helix at the C-terminal end of the first monomer is joined with the β-sheet at the N-terminal domain of the second monomer using a linker sequence derived from burgdorferi OspA serotype 1 (L1; aa 43–53 with modification [D53S] and L2; aa 65–74). The heterodimer is expressed with a posttranslationally attached N-terminal lipid moiety, indicated in line drawing. The positions of the disulfide bonds for stabilization “B” in both OspA monomer subunits are indicated in magenta. Abbreviations: N-terminal (N-term.), C-terminal (C-term.).



A fragment of a molecule, especially one that comprises an identifiable unit, e.g. an acetyl or pyridoxal phosphate group, a regulatory subunit.

Lipids: The Essential Metabolites

Lipids are hydrophobic or amphipathic small molecules which include fats, waxes, sterols, fat-soluble vitamins (such as vitamins A, D, E and K), monoglycerides, diglycerides and phospholipids. The crucial role of lipids in a cell, tissue and organ physiology is evident by their unique membrane organizing properties that provide cells with functionally distinct subcellular membrane compartments.

The main biological functions of lipids include:

  1. Energy storage and structural components of cellular membranes.
  2. Cell signaling (e.g. phospholipase C and phospholipase A2 in modulating immunological responses).
  3. Endocrine actions (e.g. steroid hormones)
  4. Essential role in signal transduction, membrane trafficking and morphogenesis.

Classification of Lipids

Lipids can be classified into 8 classes based on their chemical structure:

1. Fatty Acyls [FA]
 Fatty Acyls - Structure of Palmitic Acid The fatty acyls are a diverse group of molecules synthesized by chain elongation of an acetyl-CoA primer with malonyl-CoA (or methylmalonyl-CoA) groups that may contain a cyclic functionality and/or are substituted with heteroatoms.
Ex: Palmitic Acid

Did you figure it out yet?

Yup, they both have Triacyl (meanining 3) fatty acids or lipoproteins, Pam3cys, fungal antigen, immunosuppresive, TLR2/1 agonists attached to the N-terminals. 

Did you know;

CDC officers falsified research to fraudulently qualify the LYMErix vaccine.  They used high-passage, plasmid-dropping strains (leaving out antigens OspA and B) and knowingly raised the cutoff for the ELISA, leaving out all the neurological cases. This effectively changed the definition of the disease, from relapsing fever Borreliosis to Steere’s Knees, a purely arthritic knee outcome. The sickest people cannot get a diagnosis, and the arthritis cases likely are not looking for one! This is proven by publicly available information from the 1994 Dearborn conference along with a parallel, secret report that illustrates how the research fraud was perpetrated. We want nothing less than USDOJ prosecution of these heinous acts.




As the saying goes, “Those who fail history are destined to repeat it”. I say those who repeat it are destined to fail.

I don’t know about you but I’m not getting in line.






Published by


RN for 24 years. Activist for TRUTH in Healthcare. Lyme Warrior. Battling this disease since the late 1980's

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: